Literature DB >> 20357616

Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence.

Akiko Miyagi Maeshima1, Naobumi Tochigi, Akihiko Yoshida, Hisao Asamura, Koji Tsuta, Hitoshi Tsuda.   

Abstract

OBJECTIVE: Clarification of the clinicopathologic characteristics of patients with multiple atypical adenomatous hyperplasias (AAHs).
MATERIALS AND METHODS: The subjects were 1,639 patients who underwent lobectomy or pneumonectomy for lung tumors. The clinicopathologic features of the AAHs in the lung background and the main tumors were examined with regard to the number and the size of the AAHs, the incidence and histology of adenocarcinomas (ADs), and the outcome.
RESULTS: Thirty-two patients (2.0%) had 5 or more AAHs (ranging from 5 to 171), being present predominantly in the upper lobe (86%) and in women (75%). Among the 794 AAHs, 495 (62%) measured less than 1 mm, 170 (22%) measured 1 to less than 2 mm, 118 (15%) measured 2 to less than 5 mm, and 11 (1%) measured 5 to less than 10 mm. Twenty-eight patients (88%) had AD (1 in 18 patients and 2 to 6 in 10 patients). Thirty-two of the 51 patients with ADs (63%) had an AAH component. The incidence of ADs among the total of both AAHs and ADs was 6.0% (51 of 845). The 5-year cancer-free survival rate was 71.4%.
CONCLUSION: Five or more AAHs were seen in the background in 2.0% of lung tumors. Most of the AAHs were small, measuring less than 2 mm, and few exceeded 5 mm. Most of the patients had ADs, which were histologically suggested to be derived from AAH. However, the incidence of the AAH-AD sequence was considered to be low at the tumor basis, and the outcome of ADs was not very favorable.

Entities:  

Mesh:

Year:  2010        PMID: 20357616     DOI: 10.1097/JTO.0b013e3181ce3b73

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

1.  Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes.

Authors:  Hiroyuki Kaneda; Yoshiko Uemura; Takahito Nakano; Yohei Taniguchi; Tomohito Saito; Toshifumi Konobu; Yukihito Saito
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-24

Review 2.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

Review 3.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10

4.  Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.

Authors:  Hitoshi Dejima; Xin Hu; Runzhe Chen; Jiexin Zhang; Junya Fujimoto; Edwin R Parra; Cara Haymaker; Shawna M Hubert; Dzifa Duose; Luisa M Solis; Dan Su; Junya Fukuoka; Kazuhiro Tabata; Hoa H N Pham; Nicholas Mcgranahan; Baili Zhang; Jie Ye; Lisha Ying; Latasha Little; Curtis Gumbs; Chi-Wan Chow; Marcos Roberto Estecio; Myrna C B Godoy; Mara B Antonoff; Boris Sepesi; Harvey I Pass; Carmen Behrens; Jianhua Zhang; Ara A Vaporciyan; John V Heymach; Paul Scheet; J Jack Lee; Jia Wu; P Andrew Futreal; Alexandre Reuben; Humam Kadara; Ignacio I Wistuba; Jianjun Zhang
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene.

Authors:  Yang Wang; Zhidong Xu; Jian-Hua Mao; Ming-Szu Hung; David Hsieh; Alfred Au; David M Jablons; Liang You
Journal:  Thorac Cancer       Date:  2015-06-08       Impact factor: 3.500

Review 6.  [Lung Nodules Assessment--Analysis of Four Guidelines].

Authors:  Chunquan Liu; Yong Cui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-07-20

Review 7.  Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.

Authors:  Hongming Zhang; Liting Guo; Jibei Chen
Journal:  Onco Targets Ther       Date:  2020-04-14       Impact factor: 4.147

Review 8.  Incidental, subsolid pulmonary nodules at CT: etiology and management.

Authors:  Jessica L Seidelman; Jeffrey L Myers; Leslie E Quint
Journal:  Cancer Imaging       Date:  2013-09-23       Impact factor: 3.909

9.  [Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)].

Authors:  Gening Jiang; Chang Chen; Yuming Zhu; Dong Xie; Jie Dai; Kaiqi Jin; Yingran Shen; Haifeng Wang; Hui Li; Lanjun Zhang; Shugeng Gao; Keneng Chen; Lei Zhang; Xiao Zhou; Jingyun Shi; Hao Wang; Boxiong Xie; Lei Jiang; Jiang Fan; Deping Zhao; Qiankun Chen; Liang Duan; Wenxin He; Yiming Zhou; Hongcheng Liu; Xiaogang Zhao; Peng Zhang; Xiong Qin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-03-20

Review 10.  [Research progress of treatment strategy for pulmonary nodule].

Authors:  Feng Gao; Xiaojun Ge; Yanqing Hua
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.